Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo

29 Nov 2017

Abstract excerpt

The cytidine analogue, 5-azacytidine (AZA; 5-AZA-cR), is the primary treatment for myelodysplastic syndrome and chronic myelomonocytic leukaemia. However, only ~50% of treated patients will respond to AZA and the drivers of AZA resistance in vivo are poorly understood. To better understand the intracellular dynamics of AZA upon therapy and decipher the molecular basis for AZA resistance, we have developed a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Advanced biosensing and bioanalysis techniques
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29249821
DOI: 10.1038/leu.2017.340

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivoPMID 29249821Read ↗

Multi-omics analysis of AML cells treated with azacitidine reveals highly variable cell surface proteome remodelingSemantic proximity Read ↗

Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteomeSemantic proximity Read ↗

mRNA m5C Alteration in Azacitidine Demethylation Treatment of Acute Myeloid LeukemiaSemantic proximity Read ↗

Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic SyndromesSemantic proximity Read ↗

Azacitidine Response in Myelodysplastic Syndromes is Marked by NK-like CD8 T-Cell Expansion and CXCL12+ Reticular Cell RemodelingSemantic proximity Read ↗

Single cell multiomics reveal clonal and functional dynamics of MDS stem/progenitor cells during hypomethylating therapySemantic proximity Read ↗

Implementation of advanced analytical methods MeD-seq and LC-MS/MS for assessing the epigenetic profile of high-risk myelodysplastic syndromeSemantic proximity Read ↗

DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective studySemantic proximity Read ↗

Tracking Decitabine Incorporation into Malignant Myeloid Cell DNA in vitro and in vivo by LC-MS/MS with Enzymatic DigestionSemantic proximity Read ↗

5-azacytosine induces cytotoxicity via 5-methylcytosine depletion on chromatin-associated RNA in leukemiaSemantic proximity Read ↗

Multi-omics reveals azacitidine partially restores the hematopoiesis-supportive functions in mesenchymal stromal cells from patients with chronic myelomonocytic leukemiaSemantic proximity Read ↗

Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell lineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.